Both the causal networks of osimertinib intervention and MNK1/2 identified significantly and differentially, respectively, may evidence disease mechanisms associated with EGFR mutation-positive lung adenocarcinoma (Figure 8). Here, EGFR is linked to lung adenocarcinoma.